Skip to main content

Estrogen Receptor Negative clinical trials at UC Irvine
1 research study open to eligible people

  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

    open to eligible people ages 18 years and up

    This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

    Orange, California and other locations

Last updated: